7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Fibroma, Ossifying D018214 1 associated lipids
POEMS Syndrome D016878 1 associated lipids
Osteolysis, Essential D010015 1 associated lipids
Osteoporotic Fractures D058866 1 associated lipids
Hemangioma, Capillary D018324 1 associated lipids
Dentin Dysplasia D003805 1 associated lipids
Neoplasms, Squamous Cell D018307 1 associated lipids
Cleidocranial Dysplasia D002973 1 associated lipids
Prediabetic State D011236 1 associated lipids
Chronic Periodontitis D055113 1 associated lipids
Intracranial Hemorrhage, Traumatic D020198 1 associated lipids
Neoplastic Syndromes, Hereditary D009386 1 associated lipids
Scleroderma, Limited D045745 1 associated lipids
Rheumatic Fever D012213 1 associated lipids
Dental Pulp Exposure D003789 1 associated lipids
Dental Occlusion, Traumatic D003769 1 associated lipids
Vestibulocochlear Nerve Diseases D000160 1 associated lipids
Hemarthrosis D006395 1 associated lipids
Cherubism D002636 1 associated lipids
Arthropathy, Neurogenic D001177 1 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Tang L et al. Effects of different magnitudes of mechanical strain on Osteoblasts in vitro. 2006 Biochem. Biophys. Res. Commun. pmid:16603128
Nakashima A et al. Osteoprotegerin and bone mineral density in hemodialysis patients. 2006 Osteoporos Int pmid:16604298
Vis M et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. 2006 Ann. Rheum. Dis. pmid:16606653
Villa I et al. CGRP inhibits osteoprotegerin production in human osteoblast-like cells via cAMP/PKA-dependent pathway. 2006 Am. J. Physiol., Cell Physiol. pmid:16611736
Barreto FC et al. Osteoporosis in hemodialysis patients revisited by bone histomorphometry: a new insight into an old problem. 2006 Kidney Int. pmid:16612334
Swanson C et al. Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones. 2006 Endocrinology pmid:16614077
Demer LL and Tintut Y Pitting phosphate transport inhibitors against vascular calcification. 2006 Circ. Res. pmid:16614308
Vik A et al. Serum osteoprotegerin is inversely associated with carotid plaque echogenicity in humans. 2007 Atherosclerosis pmid:16620835
Wang Q et al. [Effect of estrogen on osteoprotegerin, osteoclast differentiation factor and macrophage colony stimulating factor mRNA expressions in ovariectomized rat bone tissue]. 2006 Nan Fang Yi Ke Da Xue Xue Bao pmid:16624776
Dynybil C et al. [The effect of osteoprotegerin on tendon-bone healing after reconstruction of the anterior cruciate ligament: a histomorphological and radiographical study in the rabbit]. 2006 Mar-Apr Z Orthop Ihre Grenzgeb pmid:16625448
Yamamoto Y et al. Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand. 2006 Endocrinology pmid:16627581
Kanzaki H et al. Cyclical tensile force on periodontal ligament cells inhibits osteoclastogenesis through OPG induction. 2006 J. Dent. Res. pmid:16632761
Bersinger NA et al. PAPP-A and osteoprotegerin, together with interleukin-8 and RANTES, are elevated in the peritoneal fluid of women with endometriosis. 2006 Am. J. Obstet. Gynecol. pmid:16635455
Wang GF et al. Influence of baicalin on the expression of receptor activator of nuclear factor-kappaB ligand in cultured human periodontal ligament cells. 2006 Pharmacology pmid:16636611
Yang M et al. The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model. 2006 Clin. Cancer Res. pmid:16638872
Hofbauer LC Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG). 2006 Ann. Endocrinol. (Paris) pmid:16639364
Matemba SF et al. Regulation of osteoclastogenesis by gap junction communication. 2006 J. Cell. Biochem. pmid:16639710
Lau YS et al. Malignant melanoma and bone resorption. 2006 Br. J. Cancer pmid:16641914
Makrygiannakis D et al. Intraarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis. 2006 Arthritis Rheum. pmid:16646024
Sylvester FA et al. Are activated T cells regulators of bone metabolism in children with Crohn disease? 2006 J. Pediatr. pmid:16647405
Coetzee M et al. Effects of arachidonic acid, docosahexaenoic acid, prostaglandin E(2) and parathyroid hormone on osteoprotegerin and RANKL secretion by MC3T3-E1 osteoblast-like cells. 2007 J. Nutr. Biochem. pmid:16650751
Li Y et al. Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. 2006 Cancer Res. pmid:16651437
Takayanagi K et al. Effects of enamel matrix derivative on bone-related mRNA expression in human periodontal ligament cells in vitro. 2006 J. Periodontol. pmid:16671883
Vik A et al. Serum osteoprotegerin in young survivors of myocardial infarction. 2006 Thromb. Haemost. pmid:16676081
Zhong N et al. [Relationship between polymorphism of parathyroid hormone and bone mineral density and relevant biochemical indicators in women]. 2006 Zhonghua Yi Xue Za Zhi pmid:16677544
Ohmori R et al. Association between osteoprotegerin gene polymorphism and coronary artery disease in Japanese men. 2006 Atherosclerosis pmid:16678184
Aoki K et al. A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss. 2006 J. Clin. Invest. pmid:16680194
Anand DV et al. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. 2006 J. Am. Coll. Cardiol. pmid:16682312
Mesquita M et al. Bone cytokines and renal osteodystrophy in peritoneal dialysis patients. 2005 Adv Perit Dial pmid:16686314
Grzegorzewska AE and Mlot M Using the ratio of serum osteoprotegerin ligand to osteoprotegerin to evaluate renal osteodystrophy in dialysis patients. 2005 Adv Perit Dial pmid:16686316
Hjelmesaeth J et al. Early posttransplant serum osteoprotegerin levels predict long-term (8-year) patient survival and cardiovascular death in renal transplant patients. 2006 J. Am. Soc. Nephrol. pmid:16687626
Chaki O [Osteoporosis]. 2006 Nippon Rinsho pmid:16689336
Hess U [The plasma cell myeloma--molecular pathogenesis and target therapies]. 2006 Ther Umsch pmid:16689452
Burton A Regulation of RANKL might reduce bone metastases . 2006 Lancet Oncol. pmid:16696160
Wang Q et al. [Effects of soybean isoflavones on expression levels of osteoprotegerin and osteoprotegerin ligand mRNAs in bone tissues of ovariectomized rats]. 2006 Zhong Xi Yi Jie He Xue Bao pmid:16696921
Liu YH et al. [Effects of kangfengshi granules on expressions of osteoprotegerin, RANKL and M-CSF in bone tissues of rats with collagen-induced arthritis]. 2006 Zhong Xi Yi Jie He Xue Bao pmid:16696922
Gannagé-Yared MH et al. Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population. 2006 Clin. Endocrinol. (Oxf) pmid:16712667
Rhee EJ et al. The relationship between four single nucleotide polymorphisms in the promoter region of the osteoprotegerin gene and aortic calcification or coronary artery disease in Koreans. 2006 Clin. Endocrinol. (Oxf) pmid:16712673
Tannehill-Gregg SH et al. The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice. 2006 Clin. Exp. Metastasis pmid:16715352
Thommesen L et al. Expression and regulation of resistin in osteoblasts and osteoclasts indicate a role in bone metabolism. 2006 J. Cell. Biochem. pmid:16721825
Liu YH et al. [Effect of Herba Epimedii flavone on the osteoblasts metabolism in vitro]. 2006 Zhongguo Zhong Yao Za Zhi pmid:16722381
Gori F et al. Wdr5, a WD-40 protein, regulates osteoblast differentiation during embryonic bone development. 2006 Dev. Biol. pmid:16730692
Geusens PP et al. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. 2006 Arthritis Rheum. pmid:16736519
Shin HH et al. Soluble glucocorticoid-induced tumor necrosis factor receptor stimulates osteoclastogenesis by down-regulation of osteoprotegerin in bone marrow stromal cells. 2006 Bone pmid:16750437
Zauli G and Secchiero P The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. 2006 Cytokine Growth Factor Rev. pmid:16750931
Tat SK et al. OPG/membranous--RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation. 2006 Bone pmid:16750945
Sasaki N and Kusano E [Bone and bone related biochemical examinations. Bone and collagen related metabolites. Measurement and clinical role of OPG]. 2006 Clin Calcium pmid:16751691
Chen G et al. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. 2006 Cancer pmid:16752412
Samadfam R et al. Implication of prostaglandin receptors in the accumulation of osteoprotegerin in human osteoblast cultures. 2006 J. Rheumatol. pmid:16755666
Nishijima Y et al. Levels of RANKL and OPG in gingival crevicular fluid during orthodontic tooth movement and effect of compression force on releases from periodontal ligament cells in vitro. 2006 Orthod Craniofac Res pmid:16764680
Chen WF and Wong MS Genistein modulates the effects of parathyroid hormone in human osteoblastic SaOS-2 cells. 2006 Br. J. Nutr. pmid:16768824
Nagae M et al. Osteoclasts play a part in pain due to the inflammation adjacent to bone. 2006 Bone pmid:16769263
Pérez-Martínez FC et al. Immunohistochemical analysis of low-grade and high-grade prostate carcinoma: relative changes of parathyroid hormone-related protein and its parathyroid hormone 1 receptor, osteoprotegerin and receptor activator of nuclear factor-kB ligand. 2007 J. Clin. Pathol. pmid:16775117
Kacena MA et al. Megakaryocyte-mediated inhibition of osteoclast development. 2006 Bone pmid:16782418
Messalli EM et al. Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women. 2007 Maturitas pmid:16787719
Wakita T et al. Increase in RANKL: OPG ratio in synovia of patients with temporomandibular joint disorder. 2006 J. Dent. Res. pmid:16798863
Shin JY et al. Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes. 2006 Diabetes Care pmid:16801598
Xiang GD et al. The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes. 2006 Diabetes pmid:16804084
Galli C et al. Osteoprotegerin and receptor activator of nuclear factor-kappa B ligand modulation by enamel matrix derivative in human alveolar osteoblasts. 2006 J. Periodontol. pmid:16805686
Holding CA et al. The correlation of RANK, RANKL and TNFalpha expression with bone loss volume and polyethylene wear debris around hip implants. 2006 Biomaterials pmid:16806459
Kazama JJ et al. Circulating osteoprotegerin affects bone metabolism in dialysis patients with mild secondary hyperparathyroidism. 2006 Ther Apher Dial pmid:16817791
Granchi D et al. Serum levels of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand as markers of periprosthetic osteolysis. 2006 J Bone Joint Surg Am pmid:16818976
Lee KS et al. An antioxidant modulates expression of receptor activator of NF-kappaB in asthma. 2006 Exp. Mol. Med. pmid:16819280
Schenk-Braat EA and Bangma CH [The search for better markers for prostate cancer than prostate-specific antigen]. 2006 Ned Tijdschr Geneeskd pmid:16821452
Fiore CE et al. Altered osteoprotegerin/RANKL ratio and low bone mineral density in celiac patients on long-term treatment with gluten-free diet. 2006 Horm. Metab. Res. pmid:16823725
Fábrega E et al. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand system in the early post-operative period of liver transplantation. 2006 May-Jun Clin Transplant pmid:16824158
Jeong JH et al. Expression of RANKL and OPG in middle ear cholesteatoma tissue. 2006 Laryngoscope pmid:16826057
Chung YH et al. Lipopolysaccharide from Prevotella nigrescens stimulates osteoclastogenesis in cocultures of bone marrow mononuclear cells and primary osteoblasts. 2006 J. Periodont. Res. pmid:16827722
Lu HK et al. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis. 2006 J. Periodont. Res. pmid:16827732
Théoleyre S et al. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK. 2006 Biochem. Biophys. Res. Commun. pmid:16828054
Valero C et al. Osteoprotegerin and bone mass in squamous cell head and neck cancer patients. 2006 Calcif. Tissue Int. pmid:16830204
Glass DA and Karsenty G Canonical Wnt signaling in osteoblasts is required for osteoclast differentiation. 2006 Ann. N. Y. Acad. Sci. pmid:16831912
Whyte MP Paget's disease of bone and genetic disorders of RANKL/OPG/RANK/NF-kappaB signaling. 2006 Ann. N. Y. Acad. Sci. pmid:16831914
Zallone A Direct and indirect estrogen actions on osteoblasts and osteoclasts. 2006 Ann. N. Y. Acad. Sci. pmid:16831916
Liu XH et al. Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system. 2006 Ann. N. Y. Acad. Sci. pmid:16831922
Matsumoto T and Abe M Bone destruction in multiple myeloma. 2006 Ann. N. Y. Acad. Sci. pmid:16831932
Brunetti G et al. The role of OPG/TRAIL complex in multiple myeloma: the OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease. 2006 Ann. N. Y. Acad. Sci. pmid:16831934
Bennett BJ et al. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. 2006 Arterioscler. Thromb. Vasc. Biol. pmid:16840715
Pepe J et al. Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance. 2006 Br. J. Haematol. pmid:16848794
Kim CH et al. Oscillatory fluid flow-induced shear stress decreases osteoclastogenesis through RANKL and OPG signaling. 2006 Bone pmid:16860618
Nemoto E et al. Regulation of cementoblast function by P. gingivalis lipopolysaccharide via TLR2. 2006 J. Dent. Res. pmid:16861291
Yamaguchi M et al. RANKL increase in compressed periodontal ligament cells from root resorption. 2006 J. Dent. Res. pmid:16861294
Grzegorzewska AE and MÅ‚ot M Serum markers of bone turnover in dialyzed patients separated according to age. 2006 Int Urol Nephrol pmid:16868703
Robertson KM et al. Cholesterol-sensing receptors, liver X receptor alpha and beta, have novel and distinct roles in osteoclast differentiation and activation. 2006 J. Bone Miner. Res. pmid:16869726
Kastritis E et al. Angiogenetic factors and biochemical markers of bone metabolism in POEMS syndrome treated with high-dose therapy and autologous stem cell support. 2006 Clin Lymphoma Myeloma pmid:16879774
Schwarz C et al. Diagnosis of renal osteodystrophy. 2006 Eur. J. Clin. Invest. pmid:16884394
Michou L et al. [Molecular analysis of Paget's disease of bone]. 2007 Apr-May Pathol. Biol. pmid:16884862
Karosi T et al. Detection of osteoprotegerin and TNF-alpha mRNA in ankylotic Stapes footplates in connection with measles virus positivity. 2006 Laryngoscope pmid:16885748
Franklin M et al. Dried plum prevents bone loss in a male osteoporosis model via IGF-I and the RANK pathway. 2006 Bone pmid:16890505
Mikosch P et al. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin in men with thyroid cancer. 2006 Eur. J. Clin. Invest. pmid:16893379
Ziółkowska H and Roszkowska-Blaim M [Osteoprotegerin and calcium-phosphorus metabolism parameters in children with chronic renal failure]. 2006 Prz. Lek. pmid:16898492
Baek KH et al. Changes in the serum sex steroids, IL-7 and RANKL-OPG system after bone marrow transplantation: influences on bone and mineral metabolism. 2006 Bone pmid:16905375
Bernstein CN Inflammatory bowel diseases as secondary causes of osteoporosis. 2006 Curr Osteoporos Rep pmid:16908001
Mochizuki Y et al. Correlation between serum osteoprotegerin and biomarkers of bone metabolism during anti-thyroid treatment in patients with Graves' disease. 2006 Horm. Res. pmid:16912510
Roudier MP et al. Effects of the RANKL inhibitor, osteoprotegerin, on the pain and histopathology of bone cancer in rats. 2006 Clin. Exp. Metastasis pmid:16912914
Kawasaki K et al. Effects of aging on RANKL and OPG levels in gingival crevicular fluid during orthodontic tooth movement. 2006 Orthod Craniofac Res pmid:16918678
Menezes R et al. Receptor activator NFkappaB-ligand and osteoprotegerin protein expression in human periapical cysts and granulomas. 2006 Oral Surg Oral Med Oral Pathol Oral Radiol Endod pmid:16920551
Neumann E [New pathophysological relevant metabolic pathways in osteoporosis. Future innovative therapies?]. 2006 Z Rheumatol pmid:16924451
Rucci N et al. Modeled microgravity stimulates osteoclastogenesis and bone resorption by increasing osteoblast RANKL/OPG ratio. 2007 J. Cell. Biochem. pmid:16927271
Wang L et al. [Inhibitory effect of diacerein on osteoclastic bone destruction and its possible mechanism of action]. 2006 Yao Xue Xue Bao pmid:16927832

Table of Content